Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
CRANBURY, N.J., March 02, 2017 -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that management will present at two upcoming investor conferences.
John Crowley, Chairman and Chief Executive Officer, will present at the Cowen & Company 37th Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2017 at 9:20 a.m. ET.
Chip Baird, Chief Financial Officer, will present at the Barclays Global Healthcare Conference 2017 in Miami, FL on Tuesday, March 14, 2017 at 11:15 a.m. E.T.
A live webcast of both presentations can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044 Media: MWW PR Sid Dinsay [email protected] (646) 381-9017 FOLD–G
